While Protagonist Therapeutics Inc has overperformed by 0.96%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTGX rose by 31.32%, with highs and lows ranging from $60.60 to $32.50, whereas the simple moving average jumped by 13.52% in the last 200 days.
On June 17, 2025, Citigroup started tracking Protagonist Therapeutics Inc (NASDAQ: PTGX) recommending Buy. A report published by Goldman on December 06, 2024, Initiated its previous ‘Neutral’ rating for PTGX. BMO Capital Markets also rated PTGX shares as ‘Outperform’, setting a target price of $62 on the company’s shares in an initiating report dated December 06, 2024. Wedbush Initiated an Outperform rating on November 05, 2024, and assigned a price target of $58. TD Cowen initiated its ‘Buy’ rating for PTGX, as published in its report on September 24, 2024. Truist’s report from September 09, 2024 suggests a price prediction of $60 for PTGX shares, giving the stock a ‘Buy’ rating. CapitalOne also rated the stock as ‘Overweight’.
Analysis of Protagonist Therapeutics Inc (PTGX)
Further, the quarter-over-quarter decrease in sales is -88.89%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Protagonist Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of 8.99% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 17.26, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and PTGX is recording an average volume of 1.04M. On a monthly basis, the volatility of the stock is set at 3.97%, whereas on a weekly basis, it is put at 4.82%, with a loss of -6.89% over the past seven days. Furthermore, long-term investors anticipate a median target price of $68.42, showing growth from the present price of $50.69, which can serve as yet another indication of whether PTGX is worth investing in or should be passed over.
How Do You Analyze Protagonist Therapeutics Inc Shares?
A leading company in the Biotechnology sector, Protagonist Therapeutics Inc (PTGX) is based in the USA. When comparing Protagonist Therapeutics Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 66.64, there is a growth in quarterly earnings of -105.68%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.86%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 102.39% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
PTGX shares are owned by institutional investors to the tune of 102.39% at present.
